Taken together, these results suggest that miR-155 in breast cancer cells enhances CXCL9/10/11 expression by suppressing SOCS1 expression and tilting the p-STAT1/p-STAT3 ratio, leading to the recruitment of effective T cells to the tumor site and subsequently an improved antitumor immune response. The gene discussed is CXCL9; the disease is breast cancer.